phrykt

Foghorn Therapeutics Inc. (FHTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of FHTX were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Foghorn Therapeutics

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FHTX

103 funds and institutions reported FHTX shares worth $220M at the end of Q2 2026, about 77% of the company. The largest holder is Flagship Pioneering, LLC with 21.6%.

Funds and institutions (13F) 77%Everyone else 23%

10 largest owners, by share of the company

Flagship Pioneering, LLC21.6%
Bvf Inc9.9%
FMR LLC (Fidelity)9.7%
Deerfield Management Company, L.P.7.5%
BlackRock, Inc.4.5%
Raymond James Financial Inc4.2%
Euclidean Capital LLC2.7%
Vanguard Capital Management LLC2.5%
Geode Capital Management, LLC1.6%
Siren, L.L.C.1.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Flagship Pioneering, LLC12.67M21.59%$61.8MNo change
Bvf Inc5.84M9.95%$28.5MNo change
FMR LLC (Fidelity)5.71M9.72%$27.8M-6%
Deerfield Management Company, L.P.4.39M7.48%$21.4MNo change
BlackRock, Inc.2.63M4.47%$12.8M+11%
Raymond James Financial Inc2.49M4.24%$12.2M-4%
Euclidean Capital LLC1.57M2.68%$7.7MNo change
Vanguard Capital Management LLC1.49M2.55%$7.3MNo change
Geode Capital Management, LLC910,8661.55%$4.4M+7%
Siren, L.L.C.720,7201.23%$3.5MNo change
State Street Corp697,4691.19%$3.4M+3%
Ameriprise Financial Inc558,6850.95%$2.7M+24%
Renaissance Technologies LLC377,9360.64%$1.8M-7%
Candriam S.C.A.313,7650.53%$1.5MNo change
Northern Trust Corp309,7750.53%$1.5M+12%
Jacobs Levy Equity Management, Inc305,4340.52%$1.5M+1%
Vanguard Portfolio Management LLC304,4320.52%$1.5M+19%
Birchview Capital, LP281,9370.48%$1.4M+0%
Vanguard Fiduciary Trust Co264,4220.45%$1.3M+10%
Qube Research & Technologies Ltd203,2960.35%$992K+150%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No FHTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FHTX short interest

Low short interest. 3.8% of FHTX shares are sold short: about 1 share in 27. Over the last 12 reports the number of shares short went up 68%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.25M FHTX shares were sold short, 3.8% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 577,107 shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short, % of all shares

3.76%May 15Oct 304.41%

Days to cover

3.9May 15Oct 3010.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.25M3.76%-8%577,1073.9
Oct 15, 20262.46M4.13%+14%2.10M1.2
Sep 30, 20262.15M3.62%+8%504,8774.3
Sep 15, 20261.99M3.36%+1%383,0295.2
Aug 31, 20261.97M3.32%+10%424,5744.6
Aug 14, 20261.79M3.01%+11%250,6587.1
Jul 31, 20261.60M2.70%+4%209,6947.7
Jul 15, 20261.54M2.62%-4%497,1703.1
Jun 30, 20261.60M2.72%+14%285,5805.6
Jun 15, 20261.39M2.38%-5%162,9288.6
May 29, 20261.47M2.51%+10%179,0088.2
May 15, 20261.34M2.28%-1%140,0469.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Foghorn Therapeutics company events

Foghorn Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, job cuts). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 1, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 24, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Apr 21, 2026AnnouncementThe Company issued a press release announcing preclinical data for multiple programs from various poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, including SMARCA2 selective inhibitor FHD-909, selective CBP, EP300 and ARID1B degrader programs. Filing
  7. Mar 11, 2026ResultsReleased financial results. Filing
  8. Feb 23, 2026LeadershipFoghorn Therapeutics Inc. announced that Ryan D. Maynard had been appointed to serve as the Company’s Chief Financial Officer, effective immediately. Filing
  9. Jan 12, 2026AnnouncementThe Company entered into securities purchase agreements with certain leading life sciences investors, relating to the issuance and sale of 2,030,314 shares of its common stock, par value $0.0001 per share and, in lieu of Common Stock, pre-funded warrants to purchase 5,421,250 shares of Common Stock. Filing
  10. Dec 4, 2025LeadershipThe Board of Directors of Foghorn Therapeutics Inc. appointed Jeff Sacher as Treasurer and interim Chief Financial Officer, effective immediately. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Foghorn Therapeutics financials

Famous investors that hold FHTX

4 of the 50 well-known investors we track reported holding FHTX in their latest 13F filing. The largest position is Jim Simons's, worth $1.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026432,339$1.5M0.0%+14%
Ken Griffin · Citadel AdvisorsQ3 2026106,479$380K0.0%-33%
Steve Cohen · Point72 Asset ManagementQ3 2026106,201$379K0.0%New
Israel Englander · Millennium ManagementQ3 202682,236$294K0.0%+54%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named FHTX in the last 120 days.

FiledHolderFormStake
Oct 5, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.6%
Oct 5, 2026BIOTECHNOLOGY VALUE FUND L P13G/A7.6%

Questions about Foghorn Therapeutics Inc. (FHTX) stock

Who owns the most FHTX stock?

The largest reported owner of Foghorn Therapeutics Inc. (FHTX) is Flagship Pioneering, LLC, with 21.6% of the company. In total, 103 funds and institutions reported holding FHTX at the end of Q2 2026, together about 77% of the shares. See the largest owners.

Are FHTX insiders buying or selling?

No FHTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in FHTX?

As of Oct 30, 2026, 2.25M FHTX shares were sold short, 3.8% of the shares outstanding, down 8.3% from the report before. At the average daily volume of 577,107 shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold FHTX?

4 of the 50 well-known investors we track reported FHTX in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $1.5M. See all holders.

Executive pay

Foghorn Therapeutics's chief executive was paid a total of $2.4M for the year ended Dec 31, 2025, up 51% from $1.6M the year before. In the last 12 months, Foghorn Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.